Compare Johnson & Johnson (JNJ) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Li Auto Inc — how do they compare? Johnson & Johnson trades at $260.67 (market cap $618.09B), while Li Auto Inc trades at $11.53 (market cap $10.71B). The key difference: Johnson & Johnson is far larger — about 57.7× Li Auto Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while Li Auto Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Li Auto Inc for 101 Days on average.
| JNJ | LI | |
|---|---|---|
Market Cap | $618.09B | $10.71B |
Volume | 6,050,983 | 1,781,143 |
Sector | Health | Consumer Cyclical |
52-Week High | $278.43 | $23.61 |
52-Week Low | $186.00 | $10.69 |
Typical Hold Time | 129 Days | 101 Days |
Enterprise Value | $646.37B | $139.58M |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Li Auto (LI) trades at $11.61, down 5.64% on the day and near 52-week lows amid delivery concerns. The technical picture is bearish with negative moving averages, while fundamentals show revenue declining from $144.5B in 2024 to $112.3B in 2025, though the company maintains a strong balance sheet with $112.8B cash. Recent Q2 2026 earnings missed expectations with a net loss of $0.25 per share, and September deliveries of 31,817 vehicles indicate volume moderation.
The outlook remains challenging with intense EV competition and margin pressure, but analyst consensus suggests 31% upside to the $15.18 price target. Key risks include execution on new model launches (Li i9, MEGA) and China's auto market slowdown, while the company's cash position provides buffer against near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
